Literature DB >> 21904134

Who performs proctectomy for rectal cancer in the United States?

Rocco Ricciardi1, Patricia L Roberts, Thomas E Read, Nancy N Baxter, Peter W Marcello, David J Schoetz.   

Abstract

BACKGROUND: There is wide variation in surgical care for rectal cancer in the United States.
OBJECTIVE: This study aimed to assess the differences in individual surgeon procedural profiles that might explain variations in the rates of restorative vs nonrestorative proctectomy for rectal cancer.
DESIGN: This study was a retrospective examination of a cohort derived from trackable state hospital discharge data from 11 states. PATIENTS: We identified all patients with rectal cancer that underwent restorative proctectomy (sphincter-sparing surgery) vs nonrestorative proctectomy (colostomy formation) over a 24-month study period (January 1, 2003 through December 31, 2004). INTERVENTION: We developed an inpatient procedural profile of each treating surgeon's practice across general surgery procedure codes and summed the number of restorative vs nonrestorative proctectomies for rectal cancer by surgeon. MAIN OUTCOME MEASURES: The primary outcome measures were nonrestorative proctectomy, mortality, and length of stay.
RESULTS: A total of 7519 proctectomies were performed for rectal cancer by 2588 surgeons. During the 24-month study period, 1003 (38.8%) surgeons performed only nonrestorative procedures for rectal cancer. On multivariate analysis, the likelihood that a surgeon performed only nonrestorative procedures was increased if that surgeon performed more integumentary procedures and decreased if the surgeon performed at least one ileoanal pouch procedure or more anorectal procedures. Patients who underwent proctectomy by surgeons who performed only nonrestorative procedures had significantly higher mortality (2.5 ± 0.7%) and longer length of stay (11.3 ± 8.8 days) in comparison with those patients treated by surgeons who performed both restorative and nonrestorative procedures (1.3 ± 0.3% mortality and 9.2 ± 6.9 days, P < .001 for both analyses). The volume of proctectomy performed significantly affected all analyses. LIMITATIONS: : The retrospective design introduces potential selection bias.
CONCLUSIONS: Over a 24-month period, 38.8% of surgeons performed only nonrestorative procedures for rectal cancer. These surgeons did not regularly perform anorectal or ileoanal pouch procedures, suggesting that they may not have a focus on colorectal disease in their practice; they had significantly higher mortality and length of stay for their patients who underwent proctectomy for rectal cancer.

Entities:  

Mesh:

Year:  2011        PMID: 21904134     DOI: 10.1097/DCR.0b013e31822867a5

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  12 in total

1.  Do Diagnostic and Procedure Codes Within Population-Based, Administrative Datasets Accurately Identify Patients with Rectal Cancer?

Authors:  Reilly P Musselman; Tara Gomes; Deanna M Rothwell; Rebecca C Auer; Husein Moloo; Robin P Boushey; Carl van Walraven
Journal:  J Gastrointest Surg       Date:  2018-12-03       Impact factor: 3.452

2.  Examining the transferability of colon and rectal operative experience on outcomes following laparoscopic rectal surgery.

Authors:  Jennie K Lee; Aristithes G Doumouras; Jeremy E Springer; Cagla Eskicioglu; Nalin Amin; Margherita Cadeddu; Dennis Hong
Journal:  Surg Endosc       Date:  2019-06-10       Impact factor: 4.584

3.  Predicting opportunities to increase utilization of laparoscopy for rectal cancer.

Authors:  Deborah S Keller; Jiejing Qiu; Anthony J Senagore
Journal:  Surg Endosc       Date:  2017-09-15       Impact factor: 4.584

Review 4.  Multidisciplinary management of rectal cancer: the OSTRICH.

Authors:  David W Dietz
Journal:  J Gastrointest Surg       Date:  2013-07-25       Impact factor: 3.452

5.  Robot-assisted intersphincteric resection facilitates an efficient sphincter-saving in patients with low rectal cancer.

Authors:  Jin Cheon Kim; Jong Lyul Lee; Abdulrahman Muaod Alotaibi; Yong Sik Yoon; Chan Wook Kim; In Ja Park
Journal:  Int J Colorectal Dis       Date:  2017-03-29       Impact factor: 2.571

6.  Oncological and anorectal functional outcomes of robot-assisted intersphincteric resection in lower rectal cancer, particularly the extent of sphincter resection and sphincter saving.

Authors:  Jin Cheon Kim; Jong Lyul Lee; Joon Woo Bong; Ji Hyun Seo; Chan Wook Kim; Seong Ho Park; Jihoon Kim
Journal:  Surg Endosc       Date:  2019-07-22       Impact factor: 4.584

7.  Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation.

Authors:  Christian P Probst; Adan Z Becerra; Christopher T Aquina; Mohamedtaki A Tejani; Steven D Wexner; Julio Garcia-Aguilar; Feza H Remzi; David W Dietz; John R T Monson; Fergal J Fleming
Journal:  J Am Coll Surg       Date:  2015-04-23       Impact factor: 6.113

Review 8.  Minimum Volume Discussion in the Treatment of Colon and Rectal Cancer: A Review of the Current Status and Relevance of Surgeon and Hospital Volume regarding Result Quality and the Impact on Health Economics.

Authors:  Karl-Heinrich Link; Peter Coy; Mark Roitman; Carola Link; Marko Kornmann; Ludger Staib
Journal:  Visc Med       Date:  2017-04-20

9.  Hospital Characteristics Associated with Stage II/III Rectal Cancer Guideline Concordant Care: Analysis of Surveillance, Epidemiology and End Results-Medicare Data.

Authors:  Mary E Charlton; Jennifer E Hrabe; Kara B Wright; Jennifer A Schlichting; Bradley D McDowell; Thorvardur R Halfdanarson; Chi Lin; Karyn B Stitzenberg; John W Cromwell
Journal:  J Gastrointest Surg       Date:  2015-12-09       Impact factor: 3.452

10.  Multi-institutional assessment of sphincter preservation for rectal cancer.

Authors:  Zaid M Abdelsattar; Sandra L Wong; Nancy J Birkmeyer; Robert K Cleary; Melissa L Times; Ryan E Figg; Nanette Peters; Robert W Krell; Darrell A Campbell; Marcia M Russell; Samantha Hendren
Journal:  Ann Surg Oncol       Date:  2014-07-08       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.